Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$-- Mln
Revenue (TTM)
$-- Mln
Net Profit (TTM)
$0 Mln
ROE
-3 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
16.2
Industry P/E
--
EV/EBITDA
0.1
Div. Yield
0 %
Debt to Equity
12
Book Value
$0.1
EPS
$-2.5
Face value
--
Shares outstanding
15,492,800
CFO
$-167.54 Mln
EBITDA
$-173.46 Mln
Net Profit
$-299.20 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
CASI Pharmaceuticals (CASI)
| -32.6 | -1.6 | -24.5 | -42.2 | -19.3 | -37.4 | -18.1 |
|
BSE Sensex
| 4.9 | 4.5 | 8.0 | 10.9 | 14.8 | 22.3 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|
|
CASI Pharmaceuticals (CASI)
| -60.2 | 300.0 | -72.9 | -4.5 | -23.1 | 23.5 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
CASI Pharmaceuticals (CASI)
|
1.9 | 30.1 | 28.5 | -39.3 | -138.0 | -301.8 | -- | 16.2 |
| 20.2 | 4,700.7 | 459.4 | 206.8 | 25.6 | 68.3 | 23.4 | 12.6 | |
| 108.0 | 5,294.4 | 432.2 | -278.3 | -64.1 | -380.9 | -- | 99.5 | |
| 59.1 | 11,366.6 | 2,937.8 | 523.9 | 23.2 | 9.3 | 22 | 2.0 | |
| 33.7 | 6,425.6 | 127.4 | -668.0 | -432.9 | -- | -- | 123.7 | |
| 74.6 | 7,961.9 | 685.5 | 132.9 | 15.6 | 20.1 | 65.3 | 11.7 | |
| 13.2 | 6,426.6 | 4,427.0 | 373.0 | -0.7 | 5.8 | 17.2 | 1.0 | |
| 63.5 | 12,254.9 | 4,413.2 | 21.3 | 7.2 | 0.6 | 316.6 | 3.3 | |
| 88.6 | 4,402.4 | 1,137.8 | 214.6 | 29.2 | 12.3 | 20.8 | 2.3 | |
| 8.7 | 10,375.3 | 14,317.0 | -3,790.1 | -23.7 | -21.4 | -- | 0.7 |
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of... melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The company's hematology/oncology assets in pipeline include CNCT19, an autologous CD19 CAR-T investigative product; BI-1206, an novel anti-Fc"RIIB antibody for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. It has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China. Read more
Chairman & CEO
Dr. Wei-Wu He Ph.D.
Chairman & CEO
Dr. Wei-Wu He Ph.D.
Headquarters
Beijing
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of CASI Pharmaceuticals Inc (CASI) stood at $ 54 Mln as on 31-Dec-24
The share price of CASI Pharmaceuticals Inc (CASI) is $1.91 (NASDAQ) as of 19-May-2025 15:28 EDT. CASI Pharmaceuticals Inc (CASI) has given a return of -19.27% in the last 3 years.
CASI Pharmaceuticals Inc (CASI) has a market capitalisation of $ 30 Mln as on 16-May-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of CASI Pharmaceuticals Inc (CASI) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the CASI Pharmaceuticals Inc (CASI) and enter the required number of quantities and click on buy to purchase the shares of CASI Pharmaceuticals Inc (CASI).
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The company's hematology/oncology assets in pipeline include CNCT19, an autologous CD19 CAR-T investigative product; BI-1206, an novel anti-Fc"RIIB antibody for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. It has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.
The CEO & director of Dr. Wei-Wu He Ph.D.. is CASI Pharmaceuticals Inc (CASI), and CFO & Sr. VP is Dr. Wei-Wu He Ph.D..
There is no promoter pledging in CASI Pharmaceuticals Inc (CASI).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,178
|
|
|
1,126
|
|
|
988
|
|
|
751
|
|
|
647
|
|
|
639
|
|
|
510
|
|
|
475
|
|
|
422
|
| CASI Pharmaceuticals Inc. (CASI) | Ratios |
|---|---|
|
Return on equity(%)
|
-301.8
|
|
Operating margin(%)
|
-130.35
|
|
Net Margin(%)
|
-137.57
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of CASI Pharmaceuticals Inc (CASI) was $0 Mln.
$-0.03
(
